ARCH vs. CERE, CNX, HCC, HNRG, AMR, ARLP, BTU, NRP, NC, and PAA
Should you be buying Arch Resources stock or one of its competitors? The main competitors of Arch Resources include Cerevel Therapeutics (CERE), CNX Resources (CNX), Warrior Met Coal (HCC), Hallador Energy (HNRG), Alpha Metallurgical Resources (AMR), Alliance Resource Partners (ARLP), Peabody Energy (BTU), Natural Resource Partners (NRP), NACCO Industries (NC), and Plains All American Pipeline (PAA).
Arch Resources (NYSE:ARCH) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap oils/energy companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
Arch Resources received 373 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 61.68% of users gave Arch Resources an outperform vote.
Arch Resources currently has a consensus target price of $177.00, indicating a potential upside of 1.77%. Cerevel Therapeutics has a consensus target price of $42.67, indicating a potential upside of 4.73%. Given Cerevel Therapeutics' higher possible upside, analysts clearly believe Cerevel Therapeutics is more favorable than Arch Resources.
Arch Resources has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Arch Resources has higher revenue and earnings than Cerevel Therapeutics.
Arch Resources has a net margin of 10.89% compared to Cerevel Therapeutics' net margin of 0.00%. Arch Resources' return on equity of 22.32% beat Cerevel Therapeutics' return on equity.
In the previous week, Arch Resources and Arch Resources both had 8 articles in the media. Arch Resources' average media sentiment score of 0.95 beat Cerevel Therapeutics' score of 0.49 indicating that Arch Resources is being referred to more favorably in the media.
88.1% of Arch Resources shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 5.4% of Arch Resources shares are held by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Arch Resources beats Cerevel Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Arch Resources News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arch Resources Competitors List
Related Companies and Tools
